BR112019023776A2 - método para tratar um câncer do sistema nervoso central (snc) em um sujeito humano, anticorpo ou um fragmento de ligação ao antígeno do mesmo, composição, composição farmacêutica, método para imageamento de um tumor em um sujeito e uso de um anticorpo ou fragmento de ligação ao antígeno do mesmo - Google Patents

método para tratar um câncer do sistema nervoso central (snc) em um sujeito humano, anticorpo ou um fragmento de ligação ao antígeno do mesmo, composição, composição farmacêutica, método para imageamento de um tumor em um sujeito e uso de um anticorpo ou fragmento de ligação ao antígeno do mesmo Download PDF

Info

Publication number
BR112019023776A2
BR112019023776A2 BR112019023776-3A BR112019023776A BR112019023776A2 BR 112019023776 A2 BR112019023776 A2 BR 112019023776A2 BR 112019023776 A BR112019023776 A BR 112019023776A BR 112019023776 A2 BR112019023776 A2 BR 112019023776A2
Authority
BR
Brazil
Prior art keywords
antibody
antigen
binding fragment
seq
amino acid
Prior art date
Application number
BR112019023776-3A
Other languages
English (en)
Portuguese (pt)
Inventor
Kim Kramer
Cheung Nai-Kong
Ole Baadsgaard
Claus J. Møller San-Pedro
Original Assignee
Memorial Sloan-Kettering Cancer Center
Y-Mabs Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan-Kettering Cancer Center, Y-Mabs Therapeutics, Inc. filed Critical Memorial Sloan-Kettering Cancer Center
Publication of BR112019023776A2 publication Critical patent/BR112019023776A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nuclear Medicine (AREA)
BR112019023776-3A 2017-05-12 2018-05-14 método para tratar um câncer do sistema nervoso central (snc) em um sujeito humano, anticorpo ou um fragmento de ligação ao antígeno do mesmo, composição, composição farmacêutica, método para imageamento de um tumor em um sujeito e uso de um anticorpo ou fragmento de ligação ao antígeno do mesmo BR112019023776A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762505558P 2017-05-12 2017-05-12
US62/505,558 2017-05-12
PCT/US2018/032559 WO2018209346A1 (en) 2017-05-12 2018-05-14 Use of anti-b7h3 antibodies for treating cancer in the central nervous system

Publications (1)

Publication Number Publication Date
BR112019023776A2 true BR112019023776A2 (pt) 2020-07-28

Family

ID=64102794

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019023776-3A BR112019023776A2 (pt) 2017-05-12 2018-05-14 método para tratar um câncer do sistema nervoso central (snc) em um sujeito humano, anticorpo ou um fragmento de ligação ao antígeno do mesmo, composição, composição farmacêutica, método para imageamento de um tumor em um sujeito e uso de um anticorpo ou fragmento de ligação ao antígeno do mesmo

Country Status (11)

Country Link
US (2) US20200197546A1 (https=)
EP (1) EP3635012A4 (https=)
JP (2) JP2020520382A (https=)
KR (1) KR20200008580A (https=)
CN (1) CN110799542A (https=)
AU (1) AU2018265888A1 (https=)
BR (1) BR112019023776A2 (https=)
CA (1) CA3062335A1 (https=)
EA (1) EA201992683A1 (https=)
RU (1) RU2019140833A (https=)
WO (1) WO2018209346A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020185897A1 (en) * 2019-03-11 2020-09-17 Biocompatibles Uk Limited Radioactive microshperes for the treatment of cns tumours
WO2021037319A1 (en) 2019-08-30 2021-03-04 Y-Mabs Therapeutics, Inc. Immunohistochemical assessment of b7-h3 expression
WO2021190586A1 (zh) * 2020-03-25 2021-09-30 江苏恒瑞医药股份有限公司 B7h3抗体-依喜替康类似物偶联物及其医药用途
CN117024591A (zh) * 2020-04-22 2023-11-10 复星凯特生物科技有限公司 抗人b7-h3的单克隆抗体及其应用
US20230293738A1 (en) * 2020-04-24 2023-09-21 Y-Mabs Therapeutics, Inc. B7H3 Antibodies with Chelators
CN112961242B (zh) * 2020-06-30 2022-01-04 广州百暨基因科技有限公司 抗b7h3抗体及其应用
WO2022167052A1 (en) * 2021-02-08 2022-08-11 Y-Mabs Therapeutics, Inc. Use of ascorbic acid as stabilizing agent for anti b7-h3 antibodies
MX2023008895A (es) 2021-02-09 2023-08-09 Medilink Therapeutics Suzhou Co Ltd Conjugado de sustancia bioactiva, metodo de preparacion y uso del mismo.
MX2023011310A (es) 2021-03-26 2023-10-05 Innate Pharma Anclajes de citocina para proteinas de celulas nk de union a nkp46.
WO2022232392A2 (en) * 2021-04-28 2022-11-03 Lyvgen Biopharma Holdings Limited Bi-specific antibodies comprising anti-b7h3 binding molecules
WO2022258691A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a
WO2022258678A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a
BR112023025331A2 (pt) 2021-06-09 2024-02-27 Innate Pharma Proteína multiespecífica, composição farmacêutica, célula recombinante, ácido nucleico ou conjunto de ácidos nucleicos, uso de uma proteína ou composição, métodos ou uso
CN116867805A (zh) * 2021-09-27 2023-10-10 盛禾(中国)生物制药有限公司 一种异源二聚体蛋白质及其应用
CN118647408A (zh) 2022-02-16 2024-09-13 苏州宜联生物医药有限公司 抗体-艾日布林或其衍生物的偶联物、其中间体、制备方法、药物组合物和用途
EP4527415A1 (en) 2022-05-18 2025-03-26 Medilink Therapeutics (Suzhou) Co., Ltd. Antibody-drug conjugate containing protein degradation agent bioactive compound, method for preparing same, and use thereof
CN119744270A (zh) * 2022-07-08 2025-04-01 盛禾(中国)生物制药有限公司 一种异源二聚体融合蛋白及其应用
WO2024208818A1 (en) 2023-04-04 2024-10-10 Innate Pharma Modular chimeric antigen receptor

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY133346A (en) * 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
JP2010523478A (ja) * 2007-03-22 2010-07-15 スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ モノクローナル抗体８ｈ９の使用
PH12012501751A1 (en) * 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
KR102485788B1 (ko) * 2014-08-27 2023-01-09 메모리얼 슬로안 케터링 캔서 센터 항체, 조성물 및 용도
US9963509B2 (en) * 2014-12-23 2018-05-08 Full Spectrum Genetics, Inc. Anti-B7H3 binding compounds and uses thereof

Also Published As

Publication number Publication date
US20240415990A1 (en) 2024-12-19
AU2018265888A1 (en) 2019-11-21
JP2020520382A (ja) 2020-07-09
EP3635012A1 (en) 2020-04-15
EP3635012A4 (en) 2020-12-30
EA201992683A1 (ru) 2020-04-23
RU2019140833A3 (https=) 2022-02-07
JP2023016969A (ja) 2023-02-02
KR20200008580A (ko) 2020-01-28
CA3062335A1 (en) 2018-11-15
CN110799542A (zh) 2020-02-14
US20200197546A1 (en) 2020-06-25
RU2019140833A (ru) 2021-06-15
WO2018209346A1 (en) 2018-11-15

Similar Documents

Publication Publication Date Title
US20240415990A1 (en) Use of anti-b7h3 antibodies for treating cancer in the central nervous system
Adams et al. A Single Treatment of Yttrium-90-labeled CHX-A ″–C6. 5 Diabody Inhibits the Growth of Established Human Tumor Xenografts in Immunodeficient Mice
JP7274646B2 (ja) 血液悪性疾患を処置するための低用量抗体に基づく方法
Foster et al. Novel theranostic agent for PET imaging and targeted radiopharmaceutical therapy of tumour-infiltrating immune cells in glioma
Bartholomä Radioimmunotherapy of solid tumors: approaches on the verge of clinical application
Zalutsky Targeted radiotherapy of brain tumours
CA2986699A1 (en) Systems and methods for determining optimum patient-specific antibody dose for tumor targeting
Ehlerding et al. Targeting angiogenesis for radioimmunotherapy with a 177Lu-labeled antibody
Bailey et al. Targeted radioimmunotherapy for embryonal tumor with multilayered rosettes
Wei et al. Engineered antibodies as cancer radiotheranostics
Kondo et al. [225Ac] Ac-and [111In] In-DOTA-trastuzumab theranostic pair: cellular dosimetry and cytotoxicity in vitro and tumour and normal tissue uptake in vivo in NRG mice with HER2-positive human breast cancer xenografts
Kameswaran et al. Preparation and preclinical evaluation of 131I‐trastuzumab for breast cancer
Tuazon et al. Yttrium-90 anti-CD45 immunotherapy followed by autologous hematopoietic cell transplantation for relapsed or refractory lymphoma
Takashima et al. Tumor targeting of 211At-labeled antibody under sodium ascorbate protection against radiolysis
Sugyo et al. Anti-tissue factor antibody-mediated immuno-SPECT imaging of tissue factor expression in mouse models of pancreatic cancer
Eriksson et al. Successful radioimmunotherapy of established syngeneic rat colon carcinoma with 211At-mAb
Kemshead et al. Dose escalation with repeated intrathecal injections of 131I-labelled MAbs for the treatment of central nervous system malignancies
AU2006242245B2 (en) Combination therapy in the treatment of cancer
KR20200103751A (ko) 센트린-1에 대한 항체, 이의 제조 방법, 및 용도
CN117813326A (zh) 基于放射的导蛋白-1的检测、伴随测试和治疗方法
ZA200704642B (en) Radiation dosimetry and blocking antibodies and methods and uses therefor in the treatment of cancer
He et al. Two-compartment model of radioimmunotherapy delivered through cerebrospinal fluid
Fu et al. Therapeutic Characterization of 131I-Labeled Humanized Anti-B7-H3 Antibodies for Radioimmunotherapy for Glioblastoma
Wolden Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastoma
WO2012032043A1 (en) 212 pb imaging

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]